{
    "clinical_study": {
        "@rank": "159849", 
        "arm_group": [
            {
                "arm_group_label": "Vitamin D and Diet", 
                "arm_group_type": "Experimental", 
                "description": "Cholecalciferol (vitamin D3) 25,000 I.U./2.5 mL oral solution. 25,000 I.U. (one bottle) per week.\nHypocaloric diet"
            }, 
            {
                "arm_group_label": "Placebo & Diet", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Oral solution mimicking cholecalciferol (vitamin D3) 25,000 I.U./2.5 mL.  One bottle per week.\nHypocaloric diet"
            }
        ], 
        "brief_summary": {
            "textblock": "Hypovitaminosis D is highly prevalent in the general population, particularly in obese\n      individuals. Besides being associated with obesity, vitamin D deficiency seems to be\n      involved in the pathogenesis of insulin resistance and low-grade chronic inflammation. In\n      addition, it has been reported that individuals with low vitamin D levels are at increased\n      risk for cardiovascular diseases. A healthy diet and weight loss are cornerstones in the\n      prevention of cardiovascular diseases. Vitamin D supplementation could increase the\n      beneficial effects of these lifestyle interventions. The purpose of this study is to assess\n      whether vitamin D supplementation in conjunction with a hypocaloric diet improves the\n      cardiometabolic profile of overweight/obese subjects to a greater extent than diet alone."
        }, 
        "brief_title": "Vitamin D Supplementation for the Prevention of Cardiovascular Risk", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Obesity", 
            "Overweight", 
            "Insulin Resistance"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Insulin Resistance", 
                "Obesity", 
                "Overweight"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  BMI\u226525 kg/m2\n\n        Exclusion Criteria:\n\n          -  Diabetes mellitus\n\n          -  Chronic kidney disease\n\n          -  Liver disease\n\n          -  Cholestasis\n\n          -  Cancer\n\n          -  Chronic bowel disease\n\n          -  Primary or secondary hyperparathyroidism\n\n          -  Treatment with drugs that may affect insulin sensitivity, weight or calcium/vitamin D\n             metabolism\n\n          -  Laxative abuse\n\n          -  Changes >10% of usual body weight in the previous 6 months\n\n          -  Alcohol or illicit drug abuse\n\n          -  Pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02020694", 
            "org_study_id": "752/11", 
            "secondary_id": "2011-003183-75"
        }, 
        "intervention": [
            {
                "arm_group_label": "Vitamin D and Diet", 
                "intervention_name": "Vitamin D", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo & Diet", 
                "intervention_name": "Placebo (for vitamin D)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Obesity", 
            "Insulin resistance", 
            "Vitamin D", 
            "Cardiovascular risk factors"
        ], 
        "lastchanged_date": "December 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rome", 
                    "country": "Italy", 
                    "zip": "00168"
                }, 
                "name": "Catholic University of Sacred Heart"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Role of Vitamin D Supplementation in the Prevention of Cardiovascular Risk Factors", 
        "overall_official": {
            "affiliation": "Catholic University of the Sacred Heart", 
            "last_name": "Andrea Giaccari, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Italy: The Italian Medicines Agency"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Insulin sensitivity will be measured with the hyperinsulinemic euglycemic clamp technique and expressed as M value, calculated from the glucose infusion rate during the last 30 min of the clamp.", 
            "measure": "Change from baseline in insulin sensitivity (M value)", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 3 months"
        }, 
        "reference": [
            {
                "PMID": "22260937", 
                "citation": "Muscogiuri G, Policola C, Prioletta A, Sorice G, Mezza T, Lassandro A, Della Casa S, Pontecorvi A, Giaccari A. Low levels of 25(OH)D and insulin-resistance: 2 unrelated features or a cause-effect in PCOS? Clin Nutr. 2012 Aug;31(4):476-80. doi: 10.1016/j.clnu.2011.12.010. Epub 2012 Jan 20."
            }, 
            {
                "PMID": "21209228", 
                "citation": "Muscogiuri G, Sorice GP, Prioletta A, Policola C, Della Casa S, Pontecorvi A, Giaccari A. Will vitamin D reduce insulin resistance? Still a long way to go. Am J Clin Nutr. 2011 Mar;93(3):672-3; author reply 673-4. doi: 10.3945/ajcn.110.009068. Epub 2011 Jan 5."
            }, 
            {
                "PMID": "20587719", 
                "citation": "Muscogiuri G, Sorice GP, Prioletta A, Policola C, Della Casa S, Pontecorvi A, Giaccari A. Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes: comment to Kayaniyil et al. Diabetes Care. 2010 Jul;33(7):e99; author reply e100. doi: 10.2337/dc10-0587."
            }, 
            {
                "PMID": "20150902", 
                "citation": "Muscogiuri G, Sorice GP, Prioletta A, Policola C, Della Casa S, Pontecorvi A, Giaccari A. 25-Hydroxyvitamin D concentration correlates with insulin-sensitivity and BMI in obesity. Obesity (Silver Spring). 2010 Oct;18(10):1906-10. doi: 10.1038/oby.2010.11. Epub 2010 Feb 11."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02020694"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Catholic University of the Sacred Heart", 
            "investigator_full_name": "Andrea Giaccari", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Oral glucose tolerance will be assessed with a standard 2-hour oral glucose tolerance test (OGTT).", 
                "measure": "Change from baseline in oral glucose tolerance", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 3 months"
            }, 
            {
                "description": "Body composition will be determined by using dual energy X-ray absorptiometry (DXA).", 
                "measure": "Change from baseline in body composition", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 3 months"
            }, 
            {
                "description": "Weight, BMI, waist and hip circumference, waist/hip ratio.", 
                "measure": "Change from baseline in anthropometric parameters", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 3 months"
            }, 
            {
                "measure": "Change form baseline in systolic and diastolic blood pressure", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 3 months"
            }, 
            {
                "description": "Serum vitamin D, PTH and calcium", 
                "measure": "Change from baseline in phosphocalcic metabolism", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 3 months"
            }, 
            {
                "description": "Interleukin-6 (IL-6), IL-10, adiponectin, TNF-\u03b1, C-reactive protein (CRP) and fibrinogen", 
                "measure": "Change from baseline in inflammatory markers", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 3 months"
            }
        ], 
        "source": "Catholic University of the Sacred Heart", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Catholic University of the Sacred Heart", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}